Dune Medical Devices Ltd.'s Novel Intraoperative Probe Effective in Assessing Lumpectomy Margins, Elusive DCIS

PHOENIX--(BUSINESS WIRE)--A novel intraoperative breast cancer probe demonstrated significant potential for reducing positive surgical margins in lumpectomy patients—including those with hard-to-detect, pre invasive, ductal carcinoma in situ (DCIS)—according to two separate studies presented here at the American Society of Breast Surgeons (ASBS) Annual Meeting. A cancer patient with positive margins typically requires a second surgery, with accompanying trauma and expense, to re-shave tumor sites for adequate tissue removal. The Dune Medical (Caesarea, Israel) probe uses Radio Frequency Spectroscopy to characterize breast tissue in real-time during surgery to determine margin malignancy status and holds promise to reduce re-excision procedures.